Boston Scientific (BSX) – Company Press Releases
-
Boston Scientific Announces Results for First Quarter 2024
-
Volato Announces Changes to Board Composition
-
Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module
-
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results
-
Scivita Medical Expands Collaboration with Boston Scientific
-
Axonics Stockholders Approve Merger Agreement with Boston Scientific
-
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
-
Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes
-
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes
-
Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference
-
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
-
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
-
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
-
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
-
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
-
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
-
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
-
NACD New England honors Waters Corp. and Devoted Health as Public and Private Company “Boards of the Year”
-
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
-
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
-
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
-
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
-
CVS Health appoints Michael F. Mahoney to its Board of Directors
-
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
-
Belo Sun Provides Update on Developments on Volta Grande Project (VGP) Permitting
-
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device
-
Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results
-
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
-
Boston Scientific Receives FDA Approval for the POLARx™ Cryoablation System
-
Privia Health Announces Changes to Board of Directors
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023
-
Boston Scientific Announces Conference Call Discussing Second Quarter 2023 Results
-
Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors
-
Belo Sun Announces 2023 AGM Voting Results
-
Boston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock
-
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
-
Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference
-
Boston Scientific Announces Results for First Quarter 2023
-
Boston Scientific Reports New Progress With Action for a Healthier, More Equitable World
-
Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results
-
Scivita Medical enters into Strategic Agreement with Boston Scientific in China
-
Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
-
Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
-
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results
-
Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
-
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
-
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2™ Aortic Valve System
Back to BSX Stock Lookup
